Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
Nanobiotix, a late-stage clinical biotechnology company, will provide an operational update and financial results for the fiscal year ending December 31, 2022, on March 28, 2023. A conference call will follow on March 29, 2023, at 2:00 PM CET/8:00 AM EDT, led by CEO Laurent Levy and CFO Bart Van Rhijn. The focus will be on year-end results and business updates. Nanobiotix's lead product, NBTXR3, a potential first-in-class oncology treatment, is being evaluated for locally advanced head and neck cancer with favorable early-phase data. The company has strategic collaborations to expand product development across tumor types.
Nanobiotix has released its latest update on the total number of voting rights and shares as of January 31, 2023. The total number of shares outstanding is 34,875,872, with 36,286,976 theoretical voting rights and 36,264,858 exercisable voting rights. This report aligns with the French Commercial Code requirements for transparency. Nanobiotix's lead product candidate, NBTXR3, aims to enhance treatment outcomes for solid tumors, particularly in head and neck cancers. For further details, visit their website at www.nanobiotix.com.
Nanobiotix disclosed key shareholder information as of December 31, 2022. The total number of shares outstanding was 34,875,872, while total voting rights were 36,287,449 (theoretical) and 36,265,331 (exercisable). The company announced the termination of its liquidity contract with Gilbert Dupont, effective December 20, 2022. This follows a prior announcement on December 21, 2022. Going forward, Nanobiotix will provide monthly updates on voting rights and shares as required by French regulations.
Nanobiotix has announced that the pivotal phase 3 NANORAY-312 study for NBTXR3 has activated sites across 80 locations globally, including the US, Europe, and Asia. This trial evaluates NBTXR3, a radioenhancer, for elderly patients with locally advanced head and neck squamous cell carcinoma who cannot use platinum-based chemotherapy. The trial, which aims to enroll 500 patients, expects a futility analysis in the second half of 2023 and interim results in 2024. The company believes the data from previous studies support the potential of NBTXR3.
Nanobiotix (NASDAQ: NBTX) has announced the termination of its liquidity contract with Gilbert Dupont, effective December 20, 2022. This decision follows the review of the liquidity account, which held 22,118 shares and €71,489.96 in cash at the time of termination. The company reported a trading volume of 303,404 shares on the buy side and 306,992 shares on the sell side between July and December 2022, indicating active market participation. Despite ending this contract, Nanobiotix continues its focus on developing its lead product, NBTXR3, which has received market authorization in Europe.
Nanobiotix announced its shareholding structure as of November 30, 2022, revealing a total of 34,875,872 shares outstanding. The total number of theoretical voting rights stands at 36,286,699, while the exercisable voting rights are 36,269,556. This disclosure is in compliance with French financial regulations aimed at ensuring transparency in corporate governance. Nanobiotix continues to advance its pipeline of innovative therapeutic options for cancer treatment, leveraging its patented nanoparticle technology.
NANOBIOTIX, a late-stage clinical biotechnology company, announced that its co-founder Laurent Levy and CFO Bart Van Rhijn will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on December 1, 2022, at 9:15 AM ET / 3:15 PM CET. The chat will be available live on the company's website and archived for 90 days. NANOBIOTIX focuses on enhancing cancer treatment outcomes through its innovative nanoparticle platform, especially targeting head and neck cancers.
Nanobiotix has announced the successful completion of the dose escalation phase in a phase 1 study, evaluating NBTXR3 for patients with locally advanced pancreatic adenocarcinoma. The recommended phase 2 dose was set at 42% of the gross tumor volume, with ongoing recruitment for the expansion phase. Encouraging results include a partial response in one patient and successful local control in another leading to resectability. Safety data and early efficacy findings will be presented at a medical congress in 2023, bolstering confidence in NBTXR3's potential impact against this challenging cancer.
Nanobiotix announced promising results from its phase 1 immunotherapy study (Study 1100) involving NBTXR3 activated by radiotherapy and followed by anti-PD-1 therapy. The study demonstrated feasibility and tolerability, establishing a recommended phase 2 dose at 33% of gross tumor volume. Of 21 evaluable patients, 71.43% showed objective reduction in target lesions, with 42.86% achieving over 30%. Durable systemic disease control was observed in 38.10% of patients for over six months. A registrational phase 3 protocol submission to the FDA is planned for Q1 2023.
Nanobiotix has established the recommended Phase 2 dose for NBTXR3 combined with anti-PD-1 therapy for various cancers. Updated safety and efficacy data from Study 1100 will be presented at the SITC 2022 on November 10. The company has strengthened its scientific advisory board with twelve global medical experts, enhancing its strategic capabilities. As of September 30, 2022, Nanobiotix reported €53.5 million in cash, extending its financial runway into Q1 2024. A debt restructuring agreement with the European Investment Bank has also been finalized.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
